3° WORKSHOP CONGIUNTO SICOb – SID – SIO 7 MARZO 2014

L'integrazione tra terapia medica e chirurgica nel trattamento del paziente obeso diabetico

Recidive del diabete dopo terapia chirurgica La quantificazione del problema: quanto e dopo quanto



antonio e. pontiroli clinica medica, DISS, università degli studi di milano, ospedale san paolo



prevention of type 2 diabetes; a systematic review and meta-analysis of different intervention strategies



merlotti et al, diabetes obesity & metabolism (epub 2014)

bariatric surgery for obese type 2 diabetes: random studies

 Table 1
 Analysis of the three randomized studies comparing surgery and medical treatment in resolution of type 2 diabetes mellitus.

	LAGB vs conventional treatment	RYGB or LSG vs intensive treatment	RYGB or BPD vs conventional treatment
Study reference	1	2	3
Numbers	30 + 30	50 + 50 + 50	20 + 20 + 20
BMI (kg/m^2)	37.0	37.0	45.0
Criteria for T2DM	FBG < 126 mg/dl	HbA1c < 6.0%	FBG < 100 mg/dl
resolution	HbA1c < 6.2%		HbA1c < 6.5%
Waist (cm)	114-116	114-116	125-126
Age (y)	47.0	49.8	43.5
Duration of T2DM (y)	<2	8	6
Weight loss	25.0% vs 1.5%	29% vs 25% vs 5.4%	33% vs 33% vs 5%
Resolution	73% vs 13%	42% vs 37% vs 12%	75% vs 95% vs 0%
(without medications)	nd	29% vs 25% vs 0%	nd
Duration of study	2	1	2
(y)	dixon (JAMA 2008)	schauer (NEJM 2012)	mingrone (NEJM 2012)

LAGB = laparoscopic adjustable gastric banding; RYGB = gastric bypass; LSG = laparoscopic sleeve gastrectomy; BPD = biliopancreatic diversion; nd = not determined.

pontiroli NMCD 2012

Diabetes and Weight in Comparative Studies of Bariatric Surgery vs Conventional Medical Therapy: A Systematic Review and Meta-Analysis



Conventional, conventional treatment; Surgery, combined bariatric surgical procedures; EWL, excess weight loss; RCT, randomized controlled trial; OBS, observational study.

total number 6,131; 3,076 bariatric surgery. 3,055 conventional treatment.

ribaric et al, obes surg 2014; 24: 437-455

Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials

	Bariatric surgery Contro		ol	T2DM remission				
Study or subgroup	No of events	Total	No of events	Total	Risk ratio (95% Cl)		Weight (%)	Risk ratio (95% CI)
Adjustable gastric banding								
Dixon 2008 ²⁵ (2 years)	22	29	4	26			35.2	4.9 (2.0 to 12.4)
Subtotal	22	29	4	26		-	35.2	4.9 (2.0 to 12.4)
Test for heterogeneity: Not app	licable							
Test for overall effect: z=3.38, I	P<0.001							
Other bariatric surgery technic	ues							
Liang 2013 ²⁴ (1 year)	28	31	0	70			- 21.6	126.5 (8.0 to 2007.6)
Mingrone 2012 ¹⁶ (2 years)	34	38	0	18			→ 21.7	33.6 (2.2 to 519.3)
Schauer 2012 ¹⁸ (1 year)	34	99	0	41			→ 21.5	29.0 (1.8 to 461.8)
Subtotal	96	168	0	129		-	64.8	49.7 (10.1 to 243.9)
Test for heterogeneity: τ^2 =0.00	, χ ² =0.66,	df=2, P=0	.72, l ² =0%					
Test for overall effect: z=4.81,	P<0.001							
Total (95% CI)	118	197	4	155			100.0	22.1 (3.2 to 154.3)
Test for heterogeneity: $\tau^2=2.58$, χ ² =9.50,	df=3, P=0	.02, l ² =68%					
Test for overall effect: z=3.12,	P=0.002			0.0	0.1	1 10	200	
Test for subgroup differences: ;	χ ² =6.05, df	=1, P=0.0	01, ² =83.5%	Fa	vours ntrol	Fav bariatric sur	ours gery	

gloy et al BMJ 2013; 347: f5934

Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials

	Bariatric surgery Co		Contro	rol		final HbA1c			
Study or subgroup	Mean (SD) change (% point	Total s)	Mean (SD) change (% point	Total s)		Mean dif (95%	ference CI)	Weight (%)	Mean difference (95% CI)
Adjustable gastric banding	r -								
Dixon 2008 ²⁵ (2 years)	-1.8 (1.2)	30	-0.4 (1.3)	30		-		19.7	-1.4 (-2.0 to -0.8)
Subtotal		30		30		•		19.7	-1.4 (-2.0 to -0.8)
Test for heterogeneity: Not	applicable								
Test for overall effect: z=4.3	33, P<0.001								
Other bariatric surgery tec	hniques								
lkramuddin 2013 ¹⁹ (1 yea	r) -3.3 (1.3)	56	-1.9 (1.4)	57		+		24.4	-1.4 (-1.9 to -0.9)
Liang 2013 ²⁴ (1 year)	-4.5 (1.5)	31	-3.6 (1.4)	70		-		20.1	-0.9 (-1.5 to -0.3)
Mingrone 2012 ¹⁶ (2 years)) -3.2 (2.0)	38	-0.8 (1.1)	18				14.8	-2.4 (-3.2 to -1.6)
Schauer 2012 ¹⁸ (1 year)	-2.9 (1.7)	99	-1.4 (1.6)	41		-		21.0	-1.5 (-2.1 to -0.9)
Subtotal		224		186		•		80.3	-1.5 (-2.0 to -1.0)
Test for heterogeneity: $\tau^2 = 0$	0.17, χ ² =8.09, d	f=3, P=0	0.04, l ² =63%						
Test for overall effect: z=5.3	76, P<0.001								
Total (95% CI)		254		216		•		100.0	-1.5 (-1.9 to -1.1)
Test for heterogeneity: $\tau^2 = 0$	0.10, χ ² =8.10, d	f=4, P=0	0.09, l ² =51%						
Test for overall effect: z=7.2	28, P<0.001				10	-5 0	5	10	
Test for subgroup differenc	es: χ²=0.05, df=	1, P=0.	82, ² =0%	F	avours Dariatric	surgery		Favours control	

gloy et al BMJ 2013; 347: f5934

role of bariatric surgery as treatment for type 2 diabetes in patients who do not meet current NIH criteria: a systematic review and metaanalysis (BMI < 35 kg/m²). *parikh et al, j am coll surg 2013; 217: 527-532*



3 RCTs (290 patients BMI 30-40, with or w/o T2DM found surgery associated with greater weight loss (range, 14.4-24 kg) and glycemic control (range, 0.9-1.43 point in HbA1c) during 1 to 2 years of follow-up than nonsurgical treatment.

Observational studies (600 patients) and meta-analyses of nonsurgical therapies (> 300 RCTs) support this finding at 1 or 2 years.

maggard-gibbons et al, JAMA 2013; 309: 2250-2261

Is diabetes cured by bariatric surgery?

Criteria for diabetes and diabetes resolution in bariatric surgery studies

- 1. Interview (1) and FBG < 126 mg/dl (2)
- 2.FBG < 126/100 mg/dl, HbA1c < 7/6%, no treatments (3-4)

3.OGTT (NGT, IFG/IGT, T2DM) (5)

(1) Sjostrom, Obes Res 1999; 7: 477-484; (2) sjostrom, N Engl J Med 2004; 351: 2683-2693; (3) Buchwald, Amer J Med 2009; 122: 248-256; (4) Buse, Diabetes Care 2009; 32: 2133-2135; (5) Pontiroli, J Clin Endocrinol Metab 2002; 87: 3555-3561; Pontiroli, Diabetes Care 2005; 28: 2703-2709 Diagnosis of diabetes remission after bariatic surgery may be jeopardized by remission criteria and previous hypoglycemic treatment



Duration of diabetes, age, and female sex were associated to nonremission: 10.3 ± 9.4 vs. 4.7 ± 3.8 years, p < 0.001; 55.1 ± 9.3 vs. 51.2 ± 9.9 years, p = 0.017; 58.9 vs. 33.3%, p = 0.004, respectively

ramos-levi et al. obes surg 2013; 23: 1520-1526

Predicting the glycemic response to gastric bypass surgery in patients with type 2 diabetes



dixon et al diabetes care 2013; 36: 20-26

Factors associated with T2DM remission - recurrence

subjects	surgery	remission	recurrence
42 (1)	RYGB	64% improved	24% recurred - Low BMI- poor weight loss – high FBG
177 (2)	RYGB		43% -previous treatments
97 (3)	RYGB	Older, high BMI, use of drugs	
46 (4)	LAGB + RYGB	Duration < 4y, HbA1c < 7.1, BMI < 50	
126 (5)	RYGB	C peptide	
153 (6)	RYGB + LSG		Older age, insulin use, weight regain
269 (7)	RYGB		Weight regain

(1) digiorgi et al SOARD 2010; 6. 249-253; (2) chikunguwo et al SOARD 2010; 6: 254-259;
(3) yamaguchi et al, surg endosc 2012; 26: 2843-2847;(4) robert et al obes surg 2013; 23: 770-775; (5) aarts et al obes surg 2013; 23: 867-873; (6) jmenez et al ann surg 2012; 256: 1023-1029; (7) campos et al ABCD 2013; 26 (suppl 1): 57-62

a multisite study of long-term remission and relapse of T2DM following gastric bypass



years since surgery

predictors of relapse: high HbA1c, oral agents or insulin, low weight loss, duration of T2DM > 5 years

Arterburn et al, Obes Surg 2013; 23: 93-102.

Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus

	Whole Cohort	Gastric Bypass	Sleeve Gastrectomy	<i>P</i> 1	Gastric Banding	<i>P</i> 2
Total weight loss (%)						
Short-term	27.6 ± 10.1	30.9 ± 8.3	21.2 ± 10.6	< 0.001	16.5 ± 7.6	0.068
Long-term	25.4 ± 11.9	28.1 ± 10.9	22.2 ± 9.3	0.015	13.2 ± 10.7	0.002
EWL (%)						
Short-term	60.3 ± 24.3	66.8 ± 20.4	49.7 ± 32.5	0.029	37.0 ± 17.8	0.112
Long-term	54.9 ± 26.7	60.5 ± 24.6	49.5 ± 24.9	0.047	29.5 ± 23.4	0.004
All values are mean ± 3	SD. er surgery: Long term: 5 yr	s or more after surgery	Т2	DM durat	ion and weight l	OSS
P1: gastric bypass vs slo	eeve gastrectomy: P2: sleev	e gastrectomy vs gastric ba	nding.	odict romi	ssion and recurr	onco
100w 5%	sere gasaectomy, 1 21 sice	1%	4%	euletTenn	ssion and recur	ence
36% 34% 16% 26%		28% 31% 19% 30%	61% 52%		31% 56%	0.91059
43%		52%	229	2004	35%	20.03
24%	10%	31%	26%	30/0	3%	33%
0%	1370	1/70	9%		6% 9%	RAM
short-term Long-term Recutr Cohort (n=2:	ence short-t	Gastric bypass (n=162)	short-term Long-term Rec Sleeve gastre	ectomy (n=23)	short-term Long-term Recurr Gastric bandin	en ^{ce} g (n=32)

long-term control rates of HDL, LDL, TG, AH were 73%, 72%, 80%, and 62%, respectively. diabetic nephropathy regressed (53%) or stabilized (47%).

brethauer et al ann surg 2013; 258: 628-636

The future:

Proper identification of candidates

Avoid dichotomy between surgery and drugs

(Expectations of patients and clinicians may have to be adjusted as regards remission of type 2 diabetes after bariatric surgery, Pournaras, Br J Surg 2012; 99: 100-103)

The effect of bariatric surgery can be of limited time value, but other efffects can last longer